Chronic kidney disease stage 5 as the prognostic complement of International Staging System for multiple myeloma

Background:  Reversal of renal impairment (RI) in patients with multiple myeloma (MM) has been evaluated using the estimated glomerular filtration rate (eGFRMDRD) formula developed by the Modification of Diet in Renal Disease study group. However, the prognostic impact of eGFRMDRD at diagnosis of MM is not well studied, particularly its use in conjunction with the International Staging System (ISS).

[1]  B. Wirk.  Renal failure in multiple myeloma: a medical emergency , 2011, Bone Marrow Transplantation.

[2]  C. Hutchison,et al.  Renal impairment in multiple myeloma: time is of the essence. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Pereira,et al.  High‐dose glucocorticoids improve renal failure reversibility in patients with newly diagnosed multiple myeloma , 2011, American journal of hematology.

[4]  C. Hutchison,et al.  Modelled cost-effectiveness of high cut-off haemodialysis compared to standard haemodialysis in the management of myeloma kidney , 2011, Current medical research and opinion.

[5]  B. Barlogie,et al.  Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Dimopoulos,et al.  The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  P. Richardson,et al.  Kidney disease associated with plasma cell dyscrasias. , 2010, Blood.

[8]  Jer-Chia Tsai,et al.  Epidemiology, impact and preventive care of chronic kidney disease in Taiwan , 2010, Nephrology.

[9]  Sang-We Kim,et al.  Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma , 2010, Annals of Hematology.

[10]  B. Barlogie,et al.  Survival and years of life lost in different age cohorts of patients with multiple myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Kimura,et al.  Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: single institutional experiences over 8 years , 2010, Annals of Hematology.

[12]  S. Darby,et al.  Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  O. Sezer,et al.  Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients , 2009, European journal of haematology.

[14]  T. Shen,et al.  Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment. , 2009, Clinical lymphoma & myeloma.

[15]  D. Adu,et al.  Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[16]  M. Dimopoulos,et al.  Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration , 2009, Haematologica.

[17]  M. Dimopoulos,et al.  Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG) , 2009, Leukemia.

[18]  Hui Ting Chan,et al.  All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan , 2008, The Lancet.

[19]  M. Dimopoulos,et al.  Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. , 2007, Haematologica.

[20]  C. Suh,et al.  Comparison of Serum Beta 2-Microglobulin and 24 hour Urinary Creatinine Clearance as a Prognostic Factor in Multiple Myeloma , 2006, Journal of Korean medical science.

[21]  G. Morgan,et al.  Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Newman,et al.  Diagnostic accuracy of cystatin C as a marker of kidney disease in patients with multiple myeloma: calculated glomerular filtration rate formulas are equally useful. , 2004, Clinical Chemistry.

[24]  Kenneth C. Anderson,et al.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.

[25]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  S. Singhal,et al.  Glomerular filtration rate prior to high-dose melphalan 200 mg/m2as a surrogate marker of outcome in patients with myeloma , 2001, British Journal of Cancer.

[27]  N. Tsukamoto,et al.  Risk factors for early death in patients undergoing treatment for multiple myeloma , 2001, Annals of Hematology.

[28]  L. Knudsen,et al.  Renal failure in multiple myeloma: reversibility and impact on the prognosis , 2000, European journal of haematology.

[29]  S. Montoto,et al.  Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. , 1998, Archives of internal medicine.

[30]  E. Holmberg,et al.  Renal function in newly diagnosed multiple myeloma — A demographic study of 1353 patients , 1994, European journal of haematology.

[31]  B. Barlogie,et al.  Renal failure in multiple myeloma. Pathogenesis and prognostic implications. , 1990, Archives of internal medicine.

[32]  B. Barlogie,et al.  Renal Failure in Multiple Myeloma , 1990 .

[33]  S. Salmon,et al.  A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.

[34]  J. Yen,et al.  International Staging System predicts prognosis of Chinese patients with multiple myeloma across different calendar periods with application of novel agents , 2011, Annals of Hematology.

[35]  Terry M Therneau,et al.  Review of 1027 patients with newly diagnosed multiple myeloma. , 2003, Mayo Clinic proceedings.

[36]  Kdoqi Disclaimer.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.